日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Transvaginal sonography-guided aspiration of benign ovarian cysts: a retrospective evaluation of safety, feasibility, and economic and environmental implications

经阴道超声引导下良性卵巢囊肿穿刺术:安全性、可行性、经济性和环境影响的回顾性评估

Endres, H; Cioabla, M; Ebner, F; Janni, W; Juhasz-Boess, I; Jung, L; Lukac, S; Upadhyay, M; Dayan, D

Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay

利用仅血浆循环肿瘤DNA检测方法检测乳腺癌微小残留病灶并预测复发

Janni, W; Rack, B; Friedl, T W P; Hartkopf, A D; Wiesmüller, L; Pfister, K; Mergel, F; Fink, A; Braun, T; Mehmeti, F; Uhl, N; De Gregorio, A; Huober, J; Fehm, T; Müller, V; Rich, T A; Dustin, D J; Zhang, S; Huesmann, S T

Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: a United States Electronic Health Records database analysis

真实世界中符合NATALEE和MonarchE入组条件的HR+/HER2-早期乳腺癌患者人群特征:一项基于美国电子健康记录数据库的分析

Tarantino, P; Rugo, H S; Curigliano, G; O'Shaughnessy, J A; Janni, W; Jhaveri, K; Mouabbi, J; Brufsky, A; Hamilton, E; O'Regan, R; Santarsiero, L; Akdere, M; Ye, F; Scotchmer, A; Graff, S L

The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis

沙妥珠单抗戈维替康和曲妥珠单抗德鲁替康治疗转移性乳腺癌患者稳定期和活动期脑转移的疗效——一项多中心真实世界分析

Dannehl, D; Jakob, D; Mergel, F; Estler, A; Engler, T; Volmer, L; Frevert, M-L; Matovina, S; Englisch, A; Tegeler, C M; Rohner, A; Seller, A; Hahn, M; Pfister, K; Fink, A; Popp, I; Lorenz, S; Tabatabai, G; Juhasz-Böss, I; Janni, W; Brucker, S; Taran, F-A; Hartkopf, A; Schäffler, H

Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)

一项随机、开放标签的 II 期研究的长期结果比较了卡巴他赛与紫杉醇作为三阴性或管腔 B/HER2 阴性乳腺癌患者的新辅助治疗(GENEVIEVE)

Meyer-Wilmes, P; Huober, J; Untch, M; Blohmer, J-U; Janni, W; Denkert, C; Klare, P; Link, T; Rhiem, K; Bayer, C; Reinisch, M; Bjelic-Radisic, V; Zahm, D M; Hanusch, C; Solbach, C; Heinrich, G; Hartkopf, A D; Schneeweiss, A; Fasching, P; Filmann, N; Nekljudova, V; Holtschmidt, J; Stickeler, E; Loibl, S

Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registry

靶向治疗在男性早期乳腺癌辅助治疗中的可行性:来自基于人群登记的真实世界数据

Frevert, M L; Dannehl, D; Jansen, L; Hermann, S; Schäffler, H; Huwer, S; Janni, W; Juhasz-Böss, I; Hartkopf, A D; Taran, F-A

Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers

早期乳腺癌新辅助化疗的当前临床实践和疗效:对来自55个乳腺癌中心的94,638例患者个体数据的分析

Ortmann, O; Blohmer, J-U; Sibert, N T; Brucker, S; Janni, W; Wöckel, A; Scharl, A; Dieng, S; Ferencz, J; Inwald, E C; Wesselmann, S; Kowalski, C

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

OlympiA III期临床试验中,奥拉帕尼辅助治疗对携带BRCA1/2种系致病性变异的高危早期乳腺癌患者的总生存期

Geyer, C E Jr; Garber, J E; Gelber, R D; Yothers, G; Taboada, M; Ross, L; Rastogi, P; Cui, K; Arahmani, A; Aktan, G; Armstrong, A C; Arnedos, M; Balmaña, J; Bergh, J; Bliss, J; Delaloge, S; Domchek, S M; Eisen, A; Elsafy, F; Fein, L E; Fielding, A; Ford, J M; Friedman, S; Gelmon, K A; Gianni, L; Gnant, M; Hollingsworth, S J; Im, S-A; Jager, A; Jóhannsson, Ó Þ; Lakhani, S R; Janni, W; Linderholm, B; Liu, T-W; Loman, N; Korde, L; Loibl, S; Lucas, P C; Marmé, F; Martinez de Dueñas, E; McConnell, R; Phillips, K-A; Piccart, M; Rossi, G; Schmutzler, R; Senkus, E; Shao, Z; Sharma, P; Singer, C F; Španić, T; Stickeler, E; Toi, M; Traina, T A; Viale, G; Zoppoli, G; Park, Y H; Yerushalmi, R; Yang, H; Pang, D; Jung, K H; Mailliez, A; Fan, Z; Tennevet, I; Zhang, J; Nagy, T; Sonke, G S; Sun, Q; Parton, M; Colleoni, M A; Schmidt, M; Brufsky, A M; Razaq, W; Kaufman, B; Cameron, D; Campbell, C; Tutt, A N J

Financial difficulties in breast cancer survivors with and without migration background in Germany-results from the prospective multicentre cohort study BRENDA II

德国乳腺癌幸存者(无论是否具有移民背景)的经济困难——来自前瞻性多中心队列研究 BRENDA II 的结果

Riccetti, N; Felberbaum, R; Flock, F; Kühn, T; Leinert, E; Schwentner, L; Singer, S; Taylor, K; Wöckel, A; Janni, W

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program

DETECT 研究计划中接受筛查的转移性乳腺癌患者循环肿瘤细胞 HER2 状态的预后意义

Müller, V; Banys-Paluchowski, M; Friedl, T W P; Fasching, P A; Schneeweiss, A; Hartkopf, A; Wallwiener, D; Rack, B; Meier-Stiegen, F; Huober, J; Rübner, M; Hoffmann, O; Müller, L; Janni, W; Wimberger, P; Jäger, B; Pantel, K; Riethdorf, S; Harbeck, N; Fehm, T